Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
$3.06
-0.3%
$2.61
$1.60
$15.04
$83.11M1.82118,220 shs220,948 shs
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
$1.31
+3.1%
$1.26
$0.92
$22.50
$76.35M0.6545,486 shs487,358 shs
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
$0.59
-5.1%
$0.66
$0.24
$3.98
$20.66M0.66191,554 shs328,058 shs
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
$5.64
+0.2%
$6.55
$3.82
$62.10
$52.07M1.9255,798 shs13,649 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
-0.16%-0.65%+31.33%+25.87%-71.68%
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
+3.15%+3.15%-0.76%-2.96%-88.26%
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
-5.14%-8.71%-1.78%+61.71%-83.87%
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
+0.18%-14.67%-13.00%+20.26%-91.44%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
1.8445 of 5 stars
3.31.00.00.01.70.81.3
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
4.2114 of 5 stars
3.03.00.04.62.73.30.6
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
4.4511 of 5 stars
3.15.00.04.40.04.21.3
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
3.9007 of 5 stars
3.12.00.04.71.92.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
2.57
Moderate Buy$8.50177.78% Upside
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
1.90
Reduce$5.50319.85% Upside
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
2.25
Hold$5.00746.88% Upside
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
2.20
Hold$80.001,318.44% Upside

Current Analyst Ratings Breakdown

Latest RLMD, IGMS, VRCA, and ANRO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/26/2025
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
5/15/2025
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$4.00 ➝ $4.00
5/14/2025
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
N/AN/AN/AN/A$5.62 per shareN/A
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
$2.68M29.39N/AN/A$0.82 per share1.60
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
N/AN/AN/AN/A$1.18 per shareN/A
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
$7.57M6.89N/AN/A($1.07) per share-5.27
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
-$61.43M-$2.34N/AN/AN/AN/A-39.35%-33.86%8/12/2025 (Estimated)
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
-$195.79M-$3.27N/AN/AN/A-36.81%-125.30%-20.61%8/13/2025 (Estimated)
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
-$79.98M-$2.51N/AN/AN/AN/A-181.26%-151.23%8/7/2025 (Estimated)
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
-$76.58M-$12.00N/AN/AN/AN/AN/A-145.63%8/13/2025 (Estimated)

Latest RLMD, IGMS, VRCA, and ANRO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
-$0.12N/AN/AN/A$0.40 millionN/A
8/13/2025Q2 2025
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
-$0.10N/AN/AN/A$4.37 millionN/A
8/12/2025Q2 2025
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
-$0.57N/AN/AN/AN/AN/A
8/7/2025Q2 2025
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
-$0.25N/AN/AN/AN/AN/A
7/31/2025Q2 2025
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
-$0.30$1.58+$1.88$1.58$3.20 million$143.62 million
5/13/2025Q1 2025
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
-$0.59-$0.53+$0.06-$0.56N/AN/A
5/13/2025Q1 2025
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
-$0.41-$0.86-$0.45-$0.86$4.25 million$0.50 million
5/13/2025Q1 2025
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
-$1.40-$1.00+$0.40-$0.10$2.53 million$3.44 million
5/12/2025Q1 2025
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
-$0.31-$0.58-$0.27-$0.58N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
N/AN/AN/AN/AN/A
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
N/AN/AN/AN/AN/A
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
N/AN/AN/AN/AN/A
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
0.15
22.53
22.53
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
N/A
5.71
5.71
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
N/A
5.29
5.29
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
N/A
1.34
1.26

Institutional Ownership

CompanyInstitutional Ownership
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
N/A
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
42.79%
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
45.24%
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
42.45%

Insider Ownership

CompanyInsider Ownership
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
11.13%
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
57.00%
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
20.70%
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
54.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
N/A27.07 million24.06 millionN/A
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
19060.12 million25.85 millionOptionable
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
1033.19 million26.32 millionOptionable
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
409.25 million4.26 millionOptionable

Recent News About These Companies

Verrica Pharmaceuticals Implements Reverse Stock Split
Verrica Shareholder Sues Board Over FDA Approval Hurdle Claims

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alto Neuroscience stock logo

Alto Neuroscience NYSE:ANRO

$3.06 -0.01 (-0.33%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$3.06 0.00 (-0.16%)
As of 08/1/2025 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.

IGM Biosciences stock logo

IGM Biosciences NASDAQ:IGMS

$1.31 +0.04 (+3.15%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$1.28 -0.03 (-2.29%)
As of 08/1/2025 05:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

Relmada Therapeutics stock logo

Relmada Therapeutics NASDAQ:RLMD

$0.59 -0.03 (-5.14%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$0.61 +0.02 (+3.32%)
As of 08/1/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

Verrica Pharmaceuticals stock logo

Verrica Pharmaceuticals NASDAQ:VRCA

$5.64 +0.01 (+0.18%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$5.66 +0.02 (+0.35%)
As of 08/1/2025 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.